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Objective: Obstructive lung disease is a leading cause of morbidity and mortality worldwide.
Some patients are readmitted, but currently predicting parameters for identifying these patients
are lacking. The aim of this study was to quantify the incidence of readmission in chronic obstruc-
tive lung disease and to identify determinants for hospital readmission.
Methods: We conducted a cohort study using the PHARMO record linkage system, including demo-
graphic details and complete medication histories of more than two million community-dwelling
residents in the Netherlands from 1985 onwards. Eligible patients were adult users of inhaled
corticosteroids (ICS) with an admission for obstructive lung disease. The outcome parameter
was readmission within a follow-up period of one year.
Results: We identified 605 ICS users with an admission for chronic obstructive lung disease, 132 of
these patients were readmitted. Readmission was associated with a high Chronic Disease Score
(adjusted HR 2.4; 95% CI 1.1e5.3). Patients using short courses of systemic corticosteroids only
(adjusted HR 0.5; 95% CI 0.4e0.8) or combined with antibiotics (adjusted HR 0.4; 95% CI 0.2e
0.6) were at decreased risk of readmission. The effect of high-dose ICS use varied over time.
Conclusions: Treatment of exacerbations out of the hospital was associatedwith a decreased risk
of readmission, while patients with multiple chronic diseases are at increased risk of readmission
for obstructive lung disease. These patients should be educated and should be invited to consul-
tationmore often to be able to detect exacerbation in an early phase and start treatment as early
as possible.
ª 2009 Elsevier Ltd. All rights reserved.755 6180; fax: þ31 88 755 5415.
cutrecht.nl (J.-W.J. Lammers).
9 Elsevier Ltd. All rights reserved.
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Obstructive lung disease is a leading cause of morbidity
and mortality 1,2 worldwide. The prevalence of Chronic
Obstructive Pulmonary disease (COPD) is 9e10% of adults
aged 40 years and older, and it is estimated that COPD will
be the number three in rank causes of death in 2030.3,4 Also,
approximately 5% of adults suffer from asthma,5 although
prevalence estimates vary worldwide from 1 to 18%.2
Hospital admission is a major burden for obstructive lung
disease from several perspectives. Hospital admission is
important from a clinical point of view. Uncontrolled
disease may put severe constraints on patients’ quality of
life,2 and severe exacerbations are associated with an
increased risk of death6 and a more rapid decline in lung
function.7 From an economical perspective, admission
contributes significantly to health care costs for chronic
obstructive lung disease.8,9
Epidemiological studies have focused on hospital
admissions as a marker for exacerbation, but most studies
focus on one admission.10e12 However, a substantial
number of these patients are readmitted to the
hospital.13,14 It would be of great value to predict these
readmissions, but currently predicting parameters are
lacking. Therefore, the aim of this study was to quantify
the incidence of readmission in patients with chronic
obstructive lung disease and to identify determinants
associated with readmission within one year.
Methods
Setting
The setting of the study was the Dutch PHARMO Record
Linkage System (www.pharmo.nl). At present, the PHARMO
RLS includes the demographic details and complete medi-
cation history of more than two million community-dwelling
residents of more than twenty-five population-defined areas
in the Netherlands from 1985 onwards.15 This database is
also linked to hospital admission records and several other
health registries, including clinical laboratory pathology
findings and general practitioner data. Since virtually all
patients in the Netherlands are registered with a single
community pharmacy, independent of prescriber, pharmacy
records are virtually complete with regard to prescription
drugs. For this study drug dispensing data and hospital
admission data were used. The computerized drug
dispensing histories contain information concerning the
dispensed drug, dispensing date, the prescriber, amount
dispensed, prescribed dosage regimen, and the estimated
duration of use. Drugs are coded according to the Anatomical
Therapeutic Chemical (ATC) classification. The hospital
admission register comprises all hospital admissions in the
Netherlands, including detailed information concerning the
primary and secondary discharge diagnoses, diagnostic,
surgical, and treatment procedures, type and frequency of
consultations with medical specialists and dates of hospital
admission and discharge. All diagnoses are coded according
to the International Classification of Diseases, 9th edition
(ICD-9-CM).15 All PHARMO linked research is in accordance
with Dutch privacy and ethical regulation.Study cohort
Using the PHARMO RLS we selected a postadmission cohort
of patients using inhaled corticosteroids (ICS). This post-
admission cohort was selected from a source population of
5327 patients using ICS in 1993. Patients were eligible for
inclusion in the source population cohort when they were
18 years or older at cohort entry, had at least one-year of
exposure history both prior to and after cohort entry, and
had at least two ICS prescriptions during follow-up. The
discharge date of the first hospital admission marked the
start of follow-up. The maximum follow-up period was one
year, in accordance to other studies.13,14,16 Follow-up
ended at either the end of data collection (December
2002), censoring of the patient in the PHARMO RLS, or the
maximum follow-up period, whichever came first. Asthma
patients who were hospitalized for more than 60 days or
patients who were hospitalized for asthma and COPD in the
source population cohort were excluded from the cohort
because of uncertainty of correct diagnosis.
Initial admission and readmission
Initial admission and readmission for obstructive lung
disease was defined as an admission with a primary
discharge diagnosis of obstructive lung disease (chronic
bronchitis, (ICD-9-CM code 491), emphysema (492), asthma
(493), and chronic airway obstruction, not elsewhere clas-
sified (496)13,14). In order to avoid including an exacerba-
tion with insufficient recovery and immediate referral to
the hospital as a readmission, the time to readmission had
to be longer than 21 days, in accordance with other
studies.17 When readmission occurred within 21 days, this
was defined as an extended first admission and the
discharge date of the early readmission was used as cohort
entry date.
Exposure and covariate assessment
Drug use was ascertained every 90 days during follow-up,13
as this is the most common length of prescriptions in
the Netherlands. For ICS use, regular use implicates
a dispensing rate of at least one prescription every three
months.18,19 The expected ICS prescription count was
calculated as follow-up time divided by 90 days. Ratios of
observed/expected ICS prescription count were calculated,
and regular ICS use was defined as ratios between 0.75 and
2.0, whereas irregular ICS use was defined as ratios <0.75
and high-dose ICS use as ratios 2.0. For systemic cortico-
steroids defined daily dose equivalents (DDD) per day were
calculated, by dividing the DDDs of all prescriptions by
follow-up time. We defined 0.5 DDD/day (equal to 5 mg
prednisone per day) as chronic systemic corticosteroid use.20
Short courses of systemic corticosteroids with a duration of
less than 30 days, or combined with less than 10 day antibi-
otic use were considered as markers of exacerbation treat-
ment out of the hospital.21e24 Antibiotics only were not
considered as exacerbation marker because of the uncer-
tainty of their indication of use.17 Because exacerbations
can occur in clusters, markers of exacerbations out of the
hospital were grouped together as a single exacerbation
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was 21 days or less.17
The number of different respiratory drugs used (ATC-
code R03) was measured as a proxy for disease severity in
accordance to other studies.14,18,23,24 Considered comor-
bidities were rhinitis (defined as use of antihistamines and/
or nasal preparations), diabetes mellitus (use of antidia-
betics), cardiovascular disease (use of b-blockers, calcium
antagonists, ACE inhibitors, AT2-antagonists, diuretics, and
statins), dyspepsia (use of H2-receptor antagonists or
proton pump inhibitors), pain or inflammation (use of
NSAIDs), depression (use of antidepressants), and anxiety
disorders (use of benzodiazepines), as these comorbidities
frequently occur in obstructive lung disease.17,25 Further-
more, we calculated the Chronic Disease Score in a one-
year period prior to cohort entry, measuring chronic disease
during a one-year period where the score increases with the
number of different chronic diseases.26
Data analysis
The time at risk for each patient was calculated as the
time from cohort entry to censoring or the end of the
follow-up period or readmission, whichever came first.
KaplaneMeier survival analysis and multivariate Cox
proportional hazards regression analysis was used to esti-
mate the strength of the association between determinants
and readmission, expressed as hazard ratios (HR) with 95%
confidence intervals (CI). Possible determinants were
included in the regression model if they were indepen-
dently associated with the outcome (at a p-value< 0.2
level). Variables least associated with the outcome in the
multivariate model were excluded in order to achieve the
most simple model with sufficient predictive value (at
a p-value< 0.05 level). All analyses were conducted using
SPSS 14.0, and STATA 10.0.
Results
Patient characteristics
We identified 605 adult ICS users with an admission for
obstructive lung disease. During follow-up, 132 read-
missions occurred. Time to readmission was equally
distributed over follow-up time with a median of 157 days,
from 23 to 365 days. The characteristics of the study
population are displayed in Table 1. The mean age was 63.7
years (SD 13.1 years) and 42.1% were women. There were
349 patients (57.7%) who used ICS regularly, 132 patients
(21.8%) with irregular ICS use, and 124 (20.5%) with high-
dose ICS use. Of all ICS, only 12 patients (2.0%) used
combination products of ICS and b2-agonists. At baseline,
142 patients (23.5%) used chronic systemic corticosteroids.
During follow-up, a large proportion of patients used short
courses of systemic corticosteroids only or combined with
antibiotics, indicating an exacerbation for obstructive lung
disease, treated out of the hospital (Table 1).
With respect to the use of other respiratory drugs, short-
acting b2-agonists were prescribed most frequently (63.1%),
followed by short-acting muscarinic antagonists (49.9%) and
long-acting b2-agonists (35.7%). There were 216 patients(35.7%) who used one or two different respiratory medi-
cations, while 232 (38.3%) used three, and 157 (26.0%) used
more than three different respiratory drugs simultaneously
at baseline. Comorbidities occurring most frequently were
cardiovascular disease (44.5%), followed by anxiety disor-
ders (30.6%) and dyspepsia (18.7%).
For patients with a readmission, medication use
preceding the first and the second admission was similar.
As shown in Table 2, patients used less short-acting b2-
agonists, following initial hospital admission (p-value
0.057).
Predictors of readmission
Subsequently, a model was created to identify determi-
nants for readmission (Table 3). Readmission for obstruc-
tive lung disease was associated with a high Chronic Disease
Score (adjusted HR 2.4; 95% CI 1.1e5.3). Of considered
comorbidities in this study, readmission was associated with
dyspepsia (adjusted HR 1.8; 95% CI 1.2e2.6).
Patients using short courses of systemic corticosteroids
only (adjusted HR 0.5; 95% CI 0.4e0.8) or combined
with antibiotics (adjust HR 0.4; 95% CI 0.2e0.6) were at
decreased risk of readmission. Readmission was not asso-
ciated with high-dose ICS use for the complete follow-
up period (adjusted HR 1.3; 95% CI 0.8e1.9). However,
patients with high-dose ICS use were less frequently read-
mitted to the hospital in the first three months of follow-up
(adjusted HR 0.1; 95% CI 0.01e0.6), but during 4e6 months
of follow-up readmission was associated with high-dose
ICS use (adjusted HR 4.0; 95% CI 2.0e8.0; Table 4 and
Fig. 1).
Discussion
In this study, we identified determinants for readmission
in obstructive lung disease. Despite regular use for a high
proportion of patients, 132 (21.8%) patients were read-
mitted within one year. Overall, readmission was associ-
ated with a high Chronic Disease Score. Of considered
comorbidities, readmission for obstructive lung disease was
associated with dyspepsia, which is a known comorbidity,
associated with aggravation of obstructive lung disease.27
Treatment of exacerbations out of the hospital with short
courses of systemic corticosteroids only or combined with
antibiotics was associated with a decreased risk of read-
mission. Overall readmission was not associated with ICS
use. However, during 4e6 months of follow-up readmission
was associated with high-dose ICS use.
Hospital admission is the most stringent definition of an
exacerbation.11,13,22 Studying hospital-based exacerbations
leads to studying patients with most severe disease as these
patients are at increased risk of admission for obstructive
lung disease.24,28 Krishnan et al. found a decrease of
adherence to ICS or systemic corticosteroids to 50% after
two weeks after hospital discharge.29 Hospital discharge
programs could decrease the risk of readmission on the
short-term,30 but the risk of readmission should also be
decreased on the long-term as severe exacerbations are
associated with an increased risk of death6 and more rapid
decline in lung function.7 Therefore, these patients need
Table 1 Baseline characteristics (NZ 605).
Characteristics Total NZ 605
Age (year) Mean (SD) 63.7 (13.1)
18e44 59 (9.8)
45e64 201 (33.2)
65 345 (57.0)
Gender Male 350 (57.9)
Female 255 (42.1)
Year of inclusion 1993e1995 336 (55.5)
1996e1998 149 (24.6)
1999e2002 120 (19.8)
Death during follow-up Yes 14 (2.3)
ICS use Regular 349 (57.7)
Irregular use 132 (21.8)
High-dose use 124 (20.5)
Chronic systemic corticosteroid usea Yes 142 (23.5)
Patients with short courses of systemic corticosteroidsb Yes 265 (43.8)
Patients with combined short courses of systemic
corticosteroids and antibioticsb
Yes 179 (29.6)
Other respiratory drugs, N (%) Short-acting b2-agonists 382 (63.1)
Long-acting b2-agonists 216 (35.7)
Short-acting muscarinic antagonists 302 (49.9)
Long-acting muscarinic antagonists 6 (1.0)
Cromones 26 (4.3)
Systemic adrenergics 38 (6.3)
Xanthine derivatives 167 (27.6)
Number of respiratory drugs 1e2 216 (35.7)
3 232 (38.3)
>3 157 (26.0)
Drugs for comorbidities, N (%) Rhinitis 99 (16.4)
Diabetes 46 (7.6)
Cardiovascular disease 269 (44.5)
Dyspepsia 113 (18.7)
Pain or inflammation 84 (13.9)
Depression 30 (5.0)
Anxiety disorder 185 (30.6)
Chronic Disease Scorec <6 72 (11.9)
6e9 324 (53.6)
>9 209 (34.5)
a Cut-off value of chronic systemic corticosteroid use is 0.50 ddd/dayZ 5 mg/day.
b During the follow-up period.
c According to Von Korff method.26
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the risk of readmission.
Comparison with other studies yielded differences
across Europe in the incidence of readmission for obstruc-
tive lung disease. Almagro et al. found that 75 (58.5%) of
129 patients were readmitted during a one-year follow-up
period in Spain.31 The study from Gudmundsson et al.
yielded a readmission rate of 60.6%, with 246 of the total
406 patients being readmitted within one year in the
Scandinavian countries.32 Our study was conducted in the
Netherlands including 605 patients. Of all patients, 132
(21.8%) were readmitted within one year. This might bea consequence of differences in exacerbation treatment
out of the hospital.
Exacerbations in obstructive lung diseasewere found to be
associated with a decrease in lung function.33,34 Other
studies have found the combination of quality of life, hospi-
talization for COPD in the previous year and hypercapnia at
discharge,31 and a lowhealth status or anxiety at discharge as
useful predictors for readmission.32 General practitioners
however need easily measurable parameters to identify
patients at high risk for readmission. Therefore,wemeasured
exacerbations as a function of medication use. Avoidance of
causal factors35 or keeping close contact with patients who
Table 2 Medication use before admission and before readmission among patients with readmission.
Characteristics NZ 132 90 Days before
admission
90 Days before
readmission
p-Value a
Chronic systemic
corticosteroid useb
45 (34.1) 37 (28.0) 0.268
Other respiratory
drugs, N (%)
Short-acting b2-agonists 87 (65.9) 74 (56.1) 0.057
Long-acting b2-agonists 48 (36.4) 56 (42.4) 0.214
Short-acting muscarinic
antagonists
73 (55.3) 84 (63.6) 0.336
Long-acting muscarinic
antagonists
0 0
Cromones 5 (3.8) 4 (3.0) 0.755
Systemic adrenergics 9 (6.8) 5 (3.8) 0.090
Xanthine derivatives 42 (31.8) 48 (36.4) 0.808
Drugs for comorbidities, N (%) Rhinitis 27 (20.5) 26 (19.7) 0.666
Diabetes 10 (7.6) 12 (9.1) 0.678
Cardiovascular disease 61 (46.2) 67 (50.8) 0.518
Dyspepsia 36 (27.3) 47 (35.6) 0.319
Pain or inflammation 19 (14.4) 18 (13.6) 0.957
Depression 7 (5.3) 4 (3.0) 0.656
Anxiety disorder 50 (37.9) 51 (38.6) 0.815
Number of respiratory drugs 0.844
1e2 42 (31.8) 42 (31.8)
3 51 (38.6) 50 (37.9)
>3 39 (29.5) 40 (30.3)
a c2 test.
b Cut-off value of chronic systemic corticosteroid use is 0.50 ddd/dayZ 5 mg/day.
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of readmission in obstructive lung disease.
Some limitations of this study may be addressed. First,
there is no information on indication for ICS use. However,
chronic treatment with ICS is only indicated for obstructive
lung disease and all patients in this study were hospitalized
for obstructive lung disease. In order to include only
patients that used ICS chronically, we censored patients
when discontinuing after one ICS prescription, in accor-
dance to other studies.36Table 3 Predictors of readmission.
Characteristics
Outcomes N 132
ICS use Regular
Irregular use
High-dose use
Use of short courses of systemic
corticosteroids
Yes
Use of combined short courses
of systemic corticosteroids and
antibiotics
Yes
Dyspepsia Yes
Chronic Disease Score <6
6e9
>9
a Adjusted for all other variables in the model.Second, we used data covering a time period between
1993 and 2002. Because no significant changes in the
guidelines in obstructive lung disease occurred for indica-
tion of ICS, the results of this study can be extrapolated to
current practice.
Unlike randomized clinical trials, observational studies
are prone to bias and criticized because of the occurrence
of immortal time bias.37,38 i.e. immortal time bias is
unlikely to play a role in this study as all participants were
at risk of readmission immediately after hospital discharge.Crude HR
(95% CI)
Adjusted HR
(95% CI)a
Reference Reference
0.7 (0.4e1.4) 0.8 (0.4e1.4)
1.2 (0.8e1.8) 1.3 (0.8e1.9)
0.4 (0.3e0.6) 0.5 (0.4e0.8)
0.3 (0.2e0.5) 0.4 (0.2e0.6)
1.9 (1.3e2.7) 1.8 (1.2e2.6)
Reference Reference
2.4 (1.1e5.2) 2.2 (1.0e4.8)
3.0 (1.4e6.7) 2.4 (1.1e5.3)
Table 4 Effect of ICS use on readmission over follow-up time.
Characteristics Crude HR
(95% CI)
Adjusted HR
(95% CI)a
0e3 months
Outcomes N 33
ICS use Regular Reference Reference
Irregular use NAb NAb
High-dose use 0.1 (0.01e0.6) 0.1 (0.01e0.6)
4e6 months
Outcomes N 36
ICS use Regular Reference Reference
Irregular use 1.1 (0.3e3.8) 1.0 (0.3e3.5)
High-dose use 4.0 (2.0e7.9) 4.0 (2.0e8.0)
6e9 months
Outcomes N 23
ICS use Regular Reference Reference
Irregular use 2.2 (0.8e6.3) 2.6 (0.9e7.6)
High-dose use 1.5 (0.6e3.9) 1.6 (0.6e4.2)
9e12 months
Outcomes N 40
ICS use Regular Reference Reference
Irregular use 1.1 (0.4e3.1) 1.2 (0.4e3.5)
High-dose use 1.1 (0.5e2.4) 1.1 (0.5e2.4)
a Adjusted for use of short courses of systemic corticosteroids, use of combined short courses of systemic corticosteroids and
antibiotics, dyspepsia, and Chronic Disease Score.
b NAZ not applicable, no readmissions occurred in the irregular ICS use group during this period.
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Figure 1 KaplaneMeier curve showing the risk of read-
mission for obstructive lung disease during the follow-up
period, categorized by ICS use. Patients with high-dose ICS use
were less frequently readmitted to the hospital in the first
three months of follow-up, but more frequently during 4e6
months of follow-up.
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as an extended first admission and the discharge date of the
early readmission was used as cohort entry date.
The beneficial effects of ICS among asthma patients are
well-documented, but these effects are more controversial
in COPD.34,37,39e43 Confounding by severity plays a major
role in studies concerning asthma or COPD.44,45 Therefore
both conditions were studied together. The international
COPD study group found a beneficial effect of ICS on the
exacerbation rate requiring treatment by the general
physician or in the hospital,39 whereas the ISOLDE study and
the TORCH study found a beneficial ICS effect on exacer-
bations treated with short courses of systemic corticoste-
roids and/or antibiotics in randomized trials.40,41 Sin and Tu
found that ICS in postadmission patients was associated
with a reduced risk of readmission,43 but there is no firm
doseeresponse relationship. Although low-dose ICS was
inferior to medium- or high-dose ICS in protecting against
mortality in COPD, high-dose was somewhat less protective
than medium-dose ICS. Moreover, readmission was not an
outcome parameter in this study.42 Soriano et al. included
primary care patients with COPD and studied survival. ICS
were found to be associated with increased survival among
these patients. However, extrapolation of these results to
patients being hospitalized is uncertain.46 Roede et al.
studied exacerbations out of the hospital, but does not take
admissions or readmissions into account.17
Blais et al. studied ICS use and the prevention of read-
mission for asthma among newly treated asthmatics without
systemic corticosteroids in an observational study.13 Blais
concluded that regular use of ICS decreased the risk ofreadmission for asthma in the period of sixteen days to six
months after admission. After this period, the beneficial
effect of ICS use disappeared, probably because of con-
founding by severity.13 These findings are in accordancewith
the results of this study that show that more severely ill
patients use more ICS. Patients with high-dose ICS use were
at decreased risk of readmission during the first threemonths
Corticosteroids in obstructive lung disease 217of follow-up (adjusted HR 0.1; 95% CI 0.001e0.6), but during
4e6 months of follow-up readmission was associated with
high-dose ICS use (adjusted HR 4.0; 95% CI 2.0e8.0; Table 4
and Fig. 1). Moreover, this paper studies readmission as well
as exacerbations treated out of the hospital. This paper adds
to the ongoing discussion about the use of ICS in patientswith
obstructive lung disease.
In conclusion, occurrence and successful treatment of
exacerbations out of the hospital was associated with
a decreased risk of readmission, while patients having
multiple chronic diseases are at increased risk of readmission
for obstructive lung disease. Readmission was associated
with high-dose ICS use during 4e6 months follow-up. These
patients should be educated and should be invited to
consultation more often to be able to detect exacerbation in
an early phase and start treatment as early as possible.Conflict of interest statement
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